AgomAb Raises €21m Series A To Regenerate Damaged Tissues

 
• By Mike Ward

Ghent, Belgium-based start-up, AgomAb Therapeutics NV secures funds and license to develop HGF-mimetic agonistic monoclonal antibodies for regeneration of damaged tissues.

Human antibody
AgomAb develops agonistic antibodies for regeneration of damaged tissues • Source: Shutterstock

More from Business

More from Scrip